xiper partner bausch health non-infecti uveiti
clearsid biomed enter partnership bausch health
exclus licens xiper non-infecti uveiti potenti
indic reiter market outperform rate increas
price target updat royalti dcf analysi bausch
agre total develop regulatori mileston payment
up-front tier royalti rang high-teen clearsid
respons develop expens xiper approv
bausch respons commerci expens believ
reduc uncertainti compani success out-licens
uveiti program multipl partnership gene therapi early-stag
compani focu develop approv xiper expect
re-submit nda xiper clearsid also amend term loan
agreement silicon valley bank mo pt york repay
princip extend interest-onli repay period updat pt
base dcf analysi assum tier royalti rate xiper milestone/
regulatori payment patent expir
partnership detail clsd receiv up-front payment bausch
agre addit consider specifi pre-launch
develop regulatori mileston potenti payment
approv addit indic net sale mileston approv
commerci clsd receiv tier royalti rang high-teen
receiv royalti first net sale clearsid
respons develop cost includ associ
xiper approv post-approv bausch respons commerci
cost clearsid respons post-approv clinic trial
bausch may termin licens agreement up-front payment
refund xiper approv februari
valuat updat updat royalty-bas dcf xiper base
new partnership agreement estim royalti first net sale
exclud net sale net
sale vs flat royalti previous includ up-front payment
approv regulatori mileston payment project
mileston payment upon net sale anoth mileston payment
net sale previous assum total total mileston
regulatori payment better-than-expect licens agreement justifi
increas target
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
except per profit oper oper end work ratetermin growth termin term loan paybackfirm term loan paybackequ o/ incl valu per month price targetpost-approv clearsid biomed inc clsd
clearsid drug discoveri exposur target larg grow market lower-cost better-quality-of-car solut
compani micro-injector xiper deliv proven steroid macula limit increas iop intraocular pressur cataract
format common steroid formul site patholog mani diseas caus blind found back eye
macula retina current drug inject directli vitreou center eye drug inject vitreou expos
front eye side effect includ cataract glaucoma steroid effect reduc swell macula side
effect limit use clearsid suprachoroid injector deliv highly-effect drug macula without expos len cataract
increas intraocular pressur glaucoma compani partner bausch health develop commerci xiper non-
infecti uveiti clearsid also multipl partnership ocular gene therapi
clinic trial risk clearsid futur valuat primarili depend upon clinic trial result uveiti current forecast risk-adjust
probabl trial success clinic trial difficult predict failur achiev clinic trial success would lead downsid
valuat
regulatori risk fda may choos approv clearsid product due data defici requir addit trial
commerci competit risk project assum success commerci clearsid program commerci
partner ophthalmolog highli competit market sever product develop failur partner properli promot
product entri new competitor may reduc sale estim valuat
partnership risk clearsid reli multipl partner advanc pipelin commerci product variou diseas indic
partner may face oper issu delay clinic failur may impact clearsid futur valuat
research analyst prepar report does/do herebi certifi view present report accord my/our
person view secur issuer discuss report mandat sec regul ac part my/our compens
directli indirectli relat specif view recommend express herein certif made
oblig set forth sec regul ac person entiti may use purpos certif made
base my/our analysi date report public i/w assum oblig updat certif reflect fact
circumst event may subsequ come my/our attent sign donald elli nazibur rahman
jmp secur current make market secur clearsid biomed inc svb group
jmp secur expect receiv intend seek compens invest bank servic clearsid biomed inc
next month
market outperform mo jmp secur expect stock price outperform relev market indic next month
market perform mp jmp secur expect stock price perform line relev market indic next month
market under-perform mu jmp secur expect stock price under-perform relev market indic next month
jmp secur research rate invest bank servic octob
stock price chart rate price chang
note first annot denot initi coverag year whichev shorter target price list target price n/a
accord finra rule chart reflect price rang chang rate price target end
recent calendar quarter action reflect note annot stock price chart jmp secur
servic
co
jmp secur llc firm compens research analyst like firm employe base firm profit includ
revenu firm institut sale trade invest bank depart well qualiti servic activ
perform intend benefit firm institut client data prepar jmp secur llc inform
purpos base inform avail public sourc believ reliabl guarante
accuraci complet opinion project express herein reflect judgment date subject chang
without notic data neither intend consid offer sell solicit basi contract
purchas secur financi product jmp secur llc affili jmp group llc harvest capit strategi llc
respect partner director offic associ may long short posit may act market maker may
purchas sell posit secur mention herein jmp secur llc affili may perform perform seek
perform invest bank advisori servic may act manag co-manag public offer secur
compani mention herein reader assum jmp secur llc solicit busi compani cover
report member sale trade depart provid oral and/or written market opinion trade strategi client
reflect person opinion stock subject firm research report research analyst discuss trade
strategi client sometim reflect short-term expect price secur subject research report
trade strategi distinct analyst fundament rate stock base upon analyst view compar
stock coverag relev time period copyright right reserv jmp secur llc jmp secur
llc member finra sipc
director research
director equiti
director sale trade
